@blunier_a98 Excited for our future, but certainly will miss working with our pharmacy and ID team! We have all accomplished so much in such a short period of time. @PHUofSCPharmRes has provided great experiences and mentorship along the way. Forever grateful for my time here as a resident!
Another wonderful year for @PHUofSCPharmRes ID PGY2 ! @JakeCrocker3 & @blunier_a98 - not enough can be said about your amazing 2 years with us.
Simply put keep your optimism, humility & servant leader mentality at the forefront.
Prisma Upstate & Mayo Clinic here they come!
Congratulations to Dr. Joseph Kohn (@Pharmateer_F3) for being selected as an ID PRN member spotlight‼️
Thank you for your dedication and significant contributions to the profession of ID 🧫🌟💊
#IDPRN#IDX
Precision daptomycin dosing faces clinical implementation barriers despite known exposure-safety concerns w high dose!
Wow!
🆕️🔥 @CIDJournal with @DosingMatters
Revolutionizing Daptomycin Dosing: A Single 7-11 Hour Sample for Pragmatic Application https://t.co/iOALEY1NWs
SAVE THE DATE! 🤩🤗
First ID PRN Learner-led Journal Club of 2024 coming to you next week. Topics include the ACORN trial & PO abx in Gram-negative bacteremia.
🗓️ Friday, Jan 12
⏰ 12 PM CT
🔗 See PRN listserv for login info
#IDXPosts#MedEd#IDtwitter
Congrats to former resident Erin Warren & current @PHUofSCPharmRes PGY1 @JakeCrocker3 on leading work on a neat case series on successful use of combo nafcillin PLUS ceftaroline in persistent MSSA bacteremia & IE.
Published in @jac_amr
https://t.co/XNTGWGPSjG
We love a stoplight table! Check out this great summary made by @moore_wjustin of PsA resistance 🦠 to beta-lactams from the recent #Breakpoints discussion with @erinmccreary, @MaggieMonogue, and @aoliverp73. Then listen to the episode for all the details: https://t.co/ez0n3ae0fR
If you live in the US, here’s the link to order your free SARS-CoV-2 testing kit (kit includes 4 home tests). Thanks @julie_justo for sharing!
https://t.co/cLss9WUhE8
Today, we amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least 6 months after completion of the vaccine’s primary series in certain populations. https://t.co/xF8h0kmF61